Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma

Special Drug Use Surveillance for Cabometyx Tablets "Hepatocellular Carcinoma"

This study is a survey in Japan of Cabozantinib tablets used to treat Japanese people with a type of liver cancer called hepatocellular carcinoma. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

The main aim of the study is to check for side effects from Cabozantinib. During the study, participants with hepatocellular carcinoma will take Cabozantinib tablets according to their clinic's standard practice. The study doctors will check for side effects from Cabozantinib for 12 months.

Inclusion Criteria:

Participants with unresectable hepatocellular carcinoma that has progressed after cancer chemotherapy (Regardless of previous treatment history)

Exclusion Criteria:

Participants who has a history of hypersensitivity to any component of cabozantinib.